Refractory Anemia With Excess Blasts in Transformation Recruiting Phase 2 Trials for Tacrolimus (DB00864)

Also known as: Refractory anemia with excess blasts in transformation / Acute myeloblastic leukemia, minimal differentiation / Refractory anaemia with excess blasts in transformation / Myelodysplastic syndrome transformation

IndicationStatusPhase
DBCOND0028567 (Refractory Anemia With Excess Blasts in Transformation)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01760655Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic MalignanciesTreatment